Almost half of people who are currently on ORLADEYO® were previously taking another preventative therapy, including an injectablea

Access a guide to use when talking to your doctor about switching

People who switched to ORLADEYO from an injectable therapy were attack free for more than 80% of the next 12 months after switching


aBased on data on file from BioCryst Pharmaceuticals, Inc. Data current as of March 2022.
bThese data are from an analysis of 34 US patients who switched from an injectable prophylaxis to ORLADEYO during a long-term safety study.
cAccording to a questionnaire that measures medication satisfaction. The efficacy and safety of ORLADEYO compared with other treatments have not been established.